12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Votrient pazopanib: Phase III data

The double-blind, international Phase III PALETTE trial in 369 patients with angiogenesis inhibitor-naïve, metastatic STS who progressed following chemotherapy showed that once-daily 800 mg Votrient met the primary endpoint of median PFS vs. placebo (4.6 vs. 1.6 months, p<0.0001). Votrient missed the secondary endpoint of median OS...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >